Cargando…

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review

INTRODUCTION: Semaglutide, a peptidic GLP-1 receptor agonist, has been clinically approved for treatment of type 2 diabetes mellitus and is available in subcutaneous and oral dosage form. Diabetes, insulin resistance, and obesity are responsible for the pathological manifestations of non-alcoholic s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahapatra, Manoj K., Karuppasamy, Muthukumar, Sahoo, Biswa M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Expert Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159769/ https://www.ncbi.nlm.nih.gov/pubmed/35650449 http://dx.doi.org/10.1007/s11095-022-03302-1

Ejemplares similares

Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes
por: Mahapatra, Manoj Kumar, et al.
Publicado: (2022)

The Safety and Tolerability of Newer Antiepileptic Drugs in Children and Adolescents
por: Kayani, Saima, et al.
Publicado: (2012)

Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
por: Inia, José A., et al.
Publicado: (2023)

Fundamental considerations in drug design
por: Mahapatra, Manoj Kumar, et al.
Publicado: (2022)

Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study
por: Richards, Jesse, et al.
Publicado: (2023)

Advances in GLP-1 treatment: focus on oral semaglutide
por: Eliaschewitz, Freddy G., et al.
Publicado: (2021)

Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
por: Kalogirou, Maria, et al.
Publicado: (2018)

A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis
por: Pan, Qi, et al.
Publicado: (2021)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
por: Ozeki, Yoshinori, et al.
Publicado: (2022)

Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis
por: Nestor, John J., et al.
Publicado: (2022)

Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
por: Williams, David M., et al.
Publicado: (2020)

The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
por: Chuong, Vicky, et al.
Publicado: (2023)

Mood Disorders, Circadian Rhythms, Melatonin and Melatonin Agonists
por: Quera Salva, M.A., et al.
Publicado: (2012)

Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
por: Williams, David M., et al.
Publicado: (2021)

“Focused Ultrasound-mediated Drug Delivery in Humans – a Path Towards Translation in Neurodegenerative Diseases”
por: Wasielewska, Joanna M., et al.
Publicado: (2022)

Inhaled β(2)-agonists in asthma management: an evolving story
por: Silva, Diana, et al.
Publicado: (2016)

Expert Opinion on Diabetes Management Challenges and Role of Basal Insulin/GLP-1 RA Fixed-Ratio Combination in People with Type 2 Diabetes from Indonesia
por: Suastika, Ketut, et al.
Publicado: (2022)

A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes
por: Webb, Neil, et al.
Publicado: (2018)

Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists
por: Okamoto, Aki, et al.
Publicado: (2021)

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide
por: Basalay, Maryna V., et al.
Publicado: (2019)

Impact on HbA1c and body weight of switching from other GLP‐1 receptor agonists to semaglutide: A model‐based approach
por: Overgaard, Rune V., et al.
Publicado: (2018)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
por: Lee, Jinmi, et al.
Publicado: (2012)

Metformin – a Future Therapy for Neurodegenerative Diseases: Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla
por: Markowicz-Piasecka, Magdalena, et al.
Publicado: (2017)

Scientific rationale for the use of α2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders
por: Arnsten, Amy F. T., et al.
Publicado: (2023)

Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs
por: Cherney, David Z.I., et al.
Publicado: (2022)

Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery
por: Rubio-Herrera, Miguel A., et al.
Publicado: (2023)

Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults
por: Howland, Robert H
Publicado: (2009)

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
por: Hartman, Mark L., et al.
Publicado: (2020)

Clinical Management of Nonalcoholic Steatohepatitis (NASH) With the Use of Thiazolidinediones and the Additive Effect of Thiazolidinediones and a GLP-1 Agonist: Case Series
por: Rojas Ortiz, Valentina, et al.
Publicado: (2021)

Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice
por: Desjardins, Eric M., et al.
Publicado: (2023)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
por: Cheng, Dihe, et al.
Publicado: (2022)

Structural Correlates of PPAR Agonist Rescue of Experimental Chronic Alcohol-Induced Steatohepatitis
por: Ramirez, Teresa, et al.
Publicado: (2012)

Acamprosate: a new tool in the battle against alcohol dependence
por: Wright, Tara M, et al.
Publicado: (2006)

The Alisma and Rhizoma decoction abates nonalcoholic steatohepatitis-associated liver injuries in mice by modulating oxidative stress and autophagy
por: Xu, Lijun, et al.
Publicado: (2019)

Smoke Abatement
Publicado: (1906)

Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide
por: McLean, Brent A., et al.
Publicado: (2021)

Alcohol related work place injuries: More Questions than Answers!
por: Mountain, David
Publicado: (2015)

Alcohol and Drug Testing in the National Trauma Data Bank: Does it Matter?
por: Elkbuli, Adel, et al.
Publicado: (2019)

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
por: Quddos, Fatima, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uklm7kh427i9v8m8grko4jfv78